Ivan Morgunov
Ivan Morgunov is the Chief Executive Officer and Cofounder of Unlimited Bio, a biotechnology company developing combinatorial gene therapies for rejuvenation, and the Founder and Board Member of Longaevus Technologies, a longevity-focused venture studio.
He is a Russian-Israeli entrepreneur with over five years of experience in technology and biotech, driven by the goal of achieving radical human life extension. Ivan is known for pioneering the integration of multiple gene therapies to combat aging as an engineering problem, operating from Próspera ZEDE, a special economic zone in Honduras with regulatory flexibility for biomedical innovation.
Ivan cofounded Unlimited Bio in April 2024 along with biomedical scientist Dr. Anna Vakhrusheva (Chief Scientific Officer) and biomedical engineer Vladimir Leshko (Chief Operating Officer) after joining Vitalia, a two-month pop-up longevity city in Próspera, where he found a like-minded community of founders, investors, and scientists.
The company received initial funding from Infinita VC, a Próspera-based fund, plus several angel investors. In October 2025, Unlimited Bio secured a strategic investment from Immortal Dragons, a $40 million purpose-driven longevity fund headquartered in Singapore. The founding mission of Unlimited Bio is ambitious: to conduct 100 clinical trials within 10 years, build multiple gene therapies under one umbrella, and combine them to combat the effects of aging. Read Keeping up with the longevity gene therapies and Immortal Dragons Backs Unlimited Bio.
Ivan views aging as a multi-system failure involving interdependent biological networks, requiring an integrated, synergistic approach that enables safe combinations of dozens of interventions. His company’s platform integrates gene therapies, biologics, plasma-based interventions, cell therapies, and small-molecule programs targeting complementary mechanisms across organ systems. Read Conquering aging: A bold bid to fix the body’s interconnected systems.
Unlimited Bio’s first therapy is a VEGF (vascular endothelial growth factor) gene therapy delivered via a plasmid, originally approved in Russia and Ukraine in 2011 for lower-limb ischemia, and has been safely treated in over 10,000 patients over 15 years. The company licensed this therapy for use in Próspera for preventive indications and launched its first product to market within six months of incorporation.
The VEGF therapy gained significant publicity when Khloé Kardashian tagged Unlimited Bio in a Facebook post about treatments she and her sister Kim received at the Eterna clinic in Mexico, and biohacking influencer Dave Asprey shared an Instagram Reel of himself receiving the treatment, reaching 1.3 million followers. Read This company is developing gene therapies for muscle growth, erectile dysfunction, and “radical longevity”.
The company’s near-term priority is the first-in-human clinical study combining two gene therapies (VEGF and follistatin) in 12 to 15 healthy participants aged 45 and older, planned for late 2025 to early 2026. This study is the first clinical evaluation of a dual gene-therapy combination in healthy individuals, designed to demonstrate the safety and synergistic rejuvenative potential of multi-gene interventions. Read In a Honduran city, biotechs create gene therapy cocktails to fight aging.
Ivan founded Longaevus Technologies, a longevity venture studio based in Cambridge, UK, in January 2022 and served as its CEO until April 2023. He currently serves on its Board of Directors. Longaevus Technologies combines the expertise of an international team of renowned scientists from major universities and organizations, with a shared goal of reversing aging across multiple hallmarks.
In August 2023, Longaevus announced the spin-off of Elastin Biosciences following breakthrough preclinical results. Elastin Biosciences, led by CEO Sherif Idriss with Chief Scientist Alexey Moskalev and Director of Research Alexander Fedintsev, successfully identified three novel drug combinations that inhibit elastin degradation and foster its deposition, leading to a 5-fold increase in elastin expression and improving aortic elasticity in aged mice in vivo. Elastin Biosciences secured an initial funding round of $2.5 million. Read Elastin Biosciences Announces Breakthrough Discovery in Elastin Restoration.
Ivan believes he could be part of “the last generation throughout human history to die from old age.” He has stated that to achieve longevity escape velocity, he needs to accelerate progress by approximately 1.4% per year. Read A slight difference between the last person to die of old age and the first person to live a thousand years and Today it is deciding whether you will be the last person who does not live to see a thousand years.
Ivan believes that regulation is the biggest bottleneck slowing progress toward anti-aging therapies, which is why he chose to operate in Próspera’s special economic zone, which has an insurance-based regulatory model. Ivan is the author of Live to the 22nd Century: Your step-by-step plan to meet the 2101 New Year healthy, outlining strategies for radical life extension. He is also a contributing author to the peer-reviewed research paper A Framework for an Effective Healthy Longevity Clinic, published in collaboration with researchers including Alexey Moskalev and Zhongjun Zhou.
As a thought leader in the longevity space, Ivan has presented at numerous conferences, including the VitaDAO Life Extension Conference at Vitalia City in February 2024, where he spoke on managing a multi-asset portfolio in longevity biotech. He has also presented at the Global Longevity Federation in Rome, the Longevity Summit Dublin, and the LongBio 2024 Longevity Biotech Conference. Listen to Unlimited Bio’s Journey to Launch a Prospera Biotech Company.
Ivan has a background in computer science. One of his driving forces for working in the longevity sector is his desire to ensure his parents live long, healthy lives. He previously lived in Tel Aviv, Israel, before relocating to Roatán, Honduras. His vision is to create an “aha moment” for humanity through longevity therapies, similar to what ChatGPT did for AI or Ozempic did for biohacking. He believes that once people see it’s possible to slow or reverse aspects of aging, governments and corporations will enter the race, accelerating progress even further.
Visit his LinkedIn profile, Medium page, and the Unlimited Bio website. Follow him on Facebook and X.